Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Colorado Anschutz

Sites in Aurora, CO

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1010
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Colorado Anschutz, Aurora, CO
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Colorado Anschutz, Aurora, CO. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 601–612 of 1,010 matching trials with a site at University of Colorado Anschutz, Aurora, CO.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 4 Interventional

Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes

NCT05498116
Status at this site: Recruiting
View directory record Official record
Conditions
Albuminuria
Interventions
Montelukast, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 30, 2026, 8:06 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

NCT03924895
Site status not listed — check the official record
View directory record Official record
Conditions
Urinary Bladder Cancer, Muscle-invasive
Interventions
Pembrolizumab, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Enfortumab Vedotin
Drug · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
39
States / cities
Mobile, Alabama • Little Rock, Arkansas • Fullerton, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 30, 2026, 8:06 PM EDT
Active, not recruiting Not applicable Interventional

Forward to Quit: A Person-centered Mobile Technology Intervention for Smoking Cessation Among Transgender Adults

NCT07181551
Site status not listed — check the official record
View directory record Official record
Conditions
Smoking Cessation
Interventions
Forward to Quit (F2Q)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 30, 2026, 8:06 PM EDT
Recruiting Phase 1 Interventional

Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis

NCT06201416
Status at this site: Recruiting
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SBT777101
Biological
Lead sponsor
Sonoma Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Scottsdale, Arizona • San Francisco, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 30, 2026, 8:06 PM EDT
Recruiting Not applicable Interventional

Simulation Trial of Telemedical Support for Paramedics

NCT06441760
Status at this site: Recruiting
View directory record Official record
Conditions
Emergencies, Cardiopulmonary Arrest, Acute Respiratory Failure, Status Epilepticus
Interventions
Video teleconsultation, Audio support
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 30, 2026, 8:06 PM EDT
Active, not recruiting No phase listed Observational

3Spine Lumbar Fusion Real World Evidence Study

NCT04823858
Site status not listed — check the official record
View directory record Official record
Conditions
Lumbar Spine Degeneration
Interventions
Lumbar Interbody Fusion
Device
Lead sponsor
3Spine
Industry
Eligibility
21 Years to 80 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
20
States / cities
Beverly Hills, California • Aurora, Colorado • Steamboat Springs, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 30, 2026, 8:06 PM EDT
Active, not recruiting Phase 2 Interventional

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)

NCT06111586
Site status not listed — check the official record
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Frexalimab, Placebo, Insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 35 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
14
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 30, 2026, 8:06 PM EDT
Not yet recruiting Not applicable Interventional

To Evaluate the Clinical Impact of the Point Powered System

NCT07135947
Site status not listed — check the official record
View directory record Official record
Conditions
Amputation; Traumatic, Hand
Interventions
Point Powered partial hand prosthetic system
Device
Lead sponsor
Point Designs
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Aurora, Colorado • Broomfield, Colorado • Lafayette, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 30, 2026, 8:06 PM EDT
Not yet recruiting Not applicable Interventional

Aerobic Exercise as a Countermeasure for Night Shift Associated Circadian Misalignment

NCT07668622
Site status not listed — check the official record
View directory record Official record
Conditions
Healthy, Circadian Misalignment
Interventions
Exercise
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 30, 2026, 8:06 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Troriluzole in Adult Participants With Spinocerebellar Ataxia

NCT03701399
Site status not listed — check the official record
View directory record Official record
Conditions
Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10
Interventions
troriluzole, Placebo
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 30, 2026, 8:06 PM EDT
Recruiting Phase 2 Interventional

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

NCT05401097
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Biopsy, Enasidenib, Ivosidenib, Venetoclax
Drug · Procedure
Lead sponsor
Alice Mims
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
4
States / cities
Aurora, Colorado • Chapel Hill, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 30, 2026, 8:06 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

NCT06088290
Site status not listed — check the official record
View directory record Official record
Conditions
Leiomyosarcoma
Interventions
Lurbinectedin, Doxorubicin
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 30, 2026, 8:06 PM EDT

About this University of Colorado Anschutz institution page

What this page lists
ClinicalTrials.gov records that list University of Colorado Anschutz in Aurora, CO as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.